Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ab680
1. Ab-680
2. 2105904-82-1
3. Ab680
4. Quemliclustat [usan]
5. J6k8wsv73a
6. Chembl4471306
7. [[(2~{r},3~{s},4~{r},5~{r})-5-[6-chloranyl-4-[[(1~{s})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic Acid
8. [[(2r,3s,4r,5r)-5-[6-chloro-4-[[(1s)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic Acid
9. Unii-j6k8wsv73a
10. Quemliclustat [inn]
11. Cd73 Inhibitor Ab-680
12. Schembl19100484
13. Gtpl10707
14. Ex-a4998
15. Bdbm50527134
16. Who 11621
17. Ac-36768
18. Ba178946
19. Hy-125286
20. Cs-0090231
21. F78354
22. (((((2r,3s,4r,5r)-5-(6-chloro-4-(((s)-1-(2-fluorophenyl)ethyl)amino)-1h-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic Acid
23. (((2r,3s,4r,5r)-5-(6-chloro-4-((s)-1-(2-fluorophenyl)ethylamino)-1h-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-ylmethoxy)(hydroxy)phosphorylmethyl)phosphonic Acid
24. 1h-pyrazolo[3,4-b]pyridin-4-amine, 6-chloro-n-[(1s)-1-(2-fluorophenyl)ethyl]-1-[5-o-[hydroxy(phosphonomethyl)phosphinyl]-beta-d-ribofuranosyl]-
25. 2-chloro-n6 -[(1s)-1-(2-fluorophenyl)ethyl]-8-aza-1,7- Dicarbaadenosine 5'- (trihydrogen 2-carbadiphosphate)
26. Qdh
| Molecular Weight | 580.8 g/mol |
|---|---|
| Molecular Formula | C20H24ClFN4O9P2 |
| XLogP3 | -0.7 |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 9 |
| Exact Mass | 580.0691082 g/mol |
| Monoisotopic Mass | 580.0691082 g/mol |
| Topological Polar Surface Area | 197 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 893 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Immune Checkpoint Inhibitors
Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies. (See all compounds classified as Immune Checkpoint Inhibitors.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Quemliclustat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Quemliclustat, including repackagers and relabelers. The FDA regulates Quemliclustat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Quemliclustat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Quemliclustat supplier is an individual or a company that provides Quemliclustat active pharmaceutical ingredient (API) or Quemliclustat finished formulations upon request. The Quemliclustat suppliers may include Quemliclustat API manufacturers, exporters, distributors and traders.
Quemliclustat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Quemliclustat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Quemliclustat GMP manufacturer or Quemliclustat GMP API supplier for your needs.
A Quemliclustat CoA (Certificate of Analysis) is a formal document that attests to Quemliclustat's compliance with Quemliclustat specifications and serves as a tool for batch-level quality control.
Quemliclustat CoA mostly includes findings from lab analyses of a specific batch. For each Quemliclustat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Quemliclustat may be tested according to a variety of international standards, such as European Pharmacopoeia (Quemliclustat EP), Quemliclustat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Quemliclustat USP).
LOOKING FOR A SUPPLIER?
